Denali Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Denali Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q3 2024.
  • Denali Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $24.9M, a 9.47% decline year-over-year.
  • Denali Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $104M, a 3.27% decline year-over-year.
  • Denali Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $108M, a 8.27% increase from 2022.
  • Denali Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $99.8M, a 17.1% increase from 2021.
  • Denali Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $85.2M, a 69.3% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $104M $24.9M -$2.6M -9.47% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $106M $25.1M -$1.47M -5.53% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $108M $27.8M -$244K -0.87% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $108M $26M +$802K +3.18% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $107M $27.5M +$2.88M +11.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $104M $26.6M +$2.63M +11% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $102M $28.1M +$1.94M +7.42% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $99.8M $25.2M +$3.1M +14% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $96.7M $24.6M +$3.58M +17.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $93.2M $23.9M +$2.8M +13.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $90.4M $26.1M +$5.12M +24.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $85.2M $22.1M +$8.26M +59.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $77M $21M +$7.75M +58.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $69.2M $21.1M +$8.65M +69.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $60.6M $21M +$10.2M +95% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $50.4M $13.8M +$4.94M +55.6% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 $45.4M $13.3M +$4.35M +48.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $41.1M $12.5M -$1.23M -8.97% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $42.3M $10.8M +$3.91M +56.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $38.4M $8.89M +$3.24M +57.4% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $35.1M $8.9M +$3.39M +61.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $31.7M $13.7M +$9M +191% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $22.7M $6.87M +$3.95M +135% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $18.8M $5.65M +$4.19M +288% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-26
Q3 2018 $14.6M $5.51M +$4.38M +388% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $10.2M $4.71M +$3.65M +345% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $6.57M $2.93M +$2.16M +282% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $4.41M $1.46M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 $1.13M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $1.06M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $765K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.